UNIPHARMA CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 13.1 TWD | +6.07% |
|
+4.38% | -11.49% |
| 04-24 | UniPharma Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 2023 | UniPharma Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 | CI |
| Sales 2022 | 128M 3.93M 314M | Sales 2023 | 103M 3.17M 253M | Capitalization | 525M 16.13M 1.29B |
|---|---|---|---|---|---|
| Net income 2022 | -6M -184K -14.73M | Net income 2023 | -21M -645K -51.55M | EV / Sales 2022 | 3.06 x |
| Net cash position 2022 | 159M 4.87M 390M | Net cash position 2023 | 174M 5.34M 427M | EV / Sales 2023 | 3.41 x |
| P/E ratio 2022 |
-85.3
x | P/E ratio 2023 |
-24.3
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 49.78% |
More Fundamentals
* Assessed data
More news
| 1 day | +6.07% | ||
| 1 week | +4.38% | ||
| Current month | -4.03% | ||
| 1 month | -6.43% | ||
| 3 months | -6.09% | ||
| 6 months | -12.08% | ||
| Current year | -11.49% |
1 week
12.20
13.10
1 month
12.2013.90
Current year
12.0014.85
1 year
12.0021.50
3 years
10.4530.60
5 years
6.1993.00
10 years
6.1993.00
| Managers | Title | Age | Since |
|---|---|---|---|
Liang Kuang Lin
CEO | Chief Executive Officer | - | 24/07/05 |
Hui Ling Chen
DFI | Director of Finance/CFO | - | 20/10/14 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Cheng Chen
CHM | Chairman | 69 | 04/06/15 |
Liang Kuang Lin
CEO | Chief Executive Officer | - | 24/07/05 |
Chia Lin Wang
BRD | Director/Board Member | - | 26/06/17 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 13.1 | +6.07% | 104,449 |
| 25/04/24 | 12.35 | -1.98% | 43,070 |
| 24/04/24 | 12.6 | -0.40% | 83,237 |
| 23/04/24 | 12.65 | +1.61% | 21,901 |
| 22/04/24 | 12.45 | -0.80% | 50,853 |
End-of-day quote Taipei Exchange, April 25, 2024
More quotes
UNI PHARMA CO., LTD. is a Taiwan-based company maily engaged in wholesale of diagnostdic reagents, medical equipment and medicines. The Company's main products include Onko-SureDR-70, for monitoring and marking after Colorectal cancer surgery;Cervi-M, using in detection of DNA methylation for Cervical cancer; EZ Detect, home use fecal occult blood test paper;RFA, cancer treatment medical equipment;Bain inj, a kind of morphine analgesics;Naloxone inj, antidote for morphine drugs overdose;Esmolol inj, ultrashort type B sympathetic nerve blockers;Fomepizole inj, a kind of alcoholic poisoning antidote;and Tambocor tab, a kind of arrhythmia treatment.
| 1st Jan change | Capi. | |
|---|---|---|
| -11.49% | 14.26M | |
| +13.93% | 198M | |
| +26.13% | 77.74M | |
| +20.48% | 65.76M |
- Stock Market
- Equities
- 6621 Stock
